MIRV in Combination With Suvemcitug for Partially Platinum-Sensitive Ovarian Cancer
NCT07934121, Phase 2, Not yet recruiting, Tongji Hospital
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | MIRV in Combination With Suvemcitug for Partially Platinum-Sensitive Ovarian Cancer | ClinicalTrials.gov |
| NCT number | NCT07934121 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Phase 2 | ClinicalTrials.gov |
| Enrollment | 80 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Tongji Hospital | ClinicalTrials.gov |
| Conditions | Platinum-Sensitive Recurrent Ovarian Cancer | ClinicalTrials.gov |
| Interventions | Mirvetuximab Soravtansine, Suvemcitug | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Overall Response Rate（ORR） | up to 24 months | Investigator-assessed ORR, including confirmed best overall response of CR or PR per RECIST v1.1. | ClinicalTrials.gov |
| Secondary | Progression-Free Survival（PFS） | up to 24 months | Investigator-assessed PFS: Defined as the time from first dose to the first documented PD per tumor assessment follow-up or death from any cause (whichever occurs first). | ClinicalTrials.gov |
| Secondary | During of response*（DoR） | up to 24 months | Investigator-assessed DOR: For patients who achieve an objective response, DOR is defined as the time from first meeting CR/PR criteria (whichever occurs first) to the date of PD or death from any cause (whichever occurs first). | ClinicalTrials.gov |
| Secondary | Overall Survival (OS) | up to 24 months | OS: Defined as the time from first dose to death from any cause (for patients lost to follow-up prior to death, the last follow-up date is typically used as the date of death). | ClinicalTrials.gov |
| Secondary | CA125 response | up to 24 months | CA125 response: Assessed according to GCIG (Gynecologic Cancer InterGroup) criteria. In the GCIG CA125 criteria, CA125 response is defined as a reduction in CA125 level of at least 50% after treatment, maintained for at least 28 days. CA125 assessment can only be performed if the patient's CA125 level is greater than twice the upper limit of normal within the 2 weeks before the start of treatment. | ClinicalTrials.gov |
| Secondary | Incidence, severity, and duration of treatment-emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs). (Assessed by the investigator per CTCAE criteria.) | up to 24 months | ClinicalTrials.gov | |
| Secondary | Incidence of Grade ≥3 treatment-related adverse events (TRAEs) assessed by the investigator. (Assessed by the investigator per CTCAE criteria.) | up to 24 months | ClinicalTrials.gov | |
| Other | Correlation between baseline tumor tissue FRα expression levels and other exploratory biomarker characteristics with ORR, PFS, DOR, and treatment-related adverse events. | up to 24 months | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)